Stockscreener 앱 받기
0.02
900.00%
0.018
전일 마감가:
$0.002
열려 있는:
$0.02
하루 거래량:
2,164
Relative Volume:
0.25
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3,900%
1개월 성능:
-85.96%
6개월 성능:
-75.69%
1년 성능:
-92.59%
1일 변동 폭
$0.02
$0.02
1주일 범위
$0.002
$0.02
52주 변동 폭
$0.0003
$0.345
Nkgen Biotech Inc Stock (NKGN) Company Profile
NKGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.02 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nkgen Biotech Inc 주식(NKGN)의 최신 뉴스
NKGen Biotech provides clarification on quotation display, trading status - TipRanks
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market - The Manila Times
Form 10-K Filed Oct 8, 2025 — NKGen Biotech clarifies OTC Expert Market quotes; Common Stock remains tradable - Stock Titan
NKGen Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
NKGen Biotech to Present on the Use of Troculeucel for - GlobeNewswire
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology - The Manila Times
NKGen to Present Troculeucel for Alzheimer's at WCN Oct 15 | NKGN Stock News - Stock Titan
NKGen Biotech (NYSE:NKGN) versus AlloVir (NASDAQ:ALVR) Critical Analysis - Defense World
NKGen Biotech Announces Consulting Agreement with Dr. Kim - MSN
NKGen Biotech Secures $2.5M in Stock Purchase Agreement - TipRanks
NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors - Investing.com Nigeria
NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors By Investing.com - Investing.com South Africa
NKGen Biotech CEO to present NK cell therapy data at China forum - Investing.com Australia
Breakthrough NK Cell Therapy for Neurodegenerative Diseases: NKGen Biotech Presents Latest Clinical Data - Stock Titan
LadRx (OTCMKTS:CYTR) & NKGen Biotech (NYSE:NKGN) Head-To-Head Analysis - Defense World
NKGen Biotech announces completion of NKMax acquisition - MSN
NKGen Biotech Acquires Majority Stake in NKMax - TipRanks
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - The Manila Times
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. - GlobeNewswire
$16.9M Strategic Acquisition: NKGen Biotech Gains Full Control of NK Cell Therapy Manufacturing & IP Portfolio - Stock Titan
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034 - GlobeNewswire
Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Neurodon, Sangamo Therapeutics, Nkgen Biotech, Asceneuron, Truebinding, Alector - MenaFN
NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN
NKGen Biotech, Inc. (NYSE:NKGN) Short Interest Update - Defense World
NKGen Biotech To Present on Allogeneic Enhanced NK Cells - GlobeNewswire
Breakthrough: NKGen's NK Cell Cancer Therapy Eliminates Need for Harsh Pre-Treatment in Solid Tumors - Stock Titan
NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit - Yahoo Finance
Critical Contrast: NKGen Biotech (NYSE:NKGN) & Cortexyme (NASDAQ:CRTX) - Defense World
NKGen Biotech Presents Troculeucel Mechanism of Action with - GlobeNewswire
Revolutionary NK Cell Therapy Transforms Moderate Alzheimer's to Mild Stage in Clinical Trial - Stock Titan
NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025 - GlobeNewswire
Revolutionary NK Cell Therapy Shows Promise in Alzheimer's Disease: Phase 1 Data Reveal Key Insights - Stock Titan
NKGen Biotech Gets FDA Expanded Access - Orange County Business Journal
NKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down - Nasdaq
FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases By Investing.com - Investing.com South Africa
FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases - Investing.com Nigeria
NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases - The Manila Times
NKGen Receives FDA Expanded Access Protocol Authorization - GlobeNewswire
FDA Grants Breakthrough Access: NKGen's NK Cell Therapy Now Available for Multiple Untreatable Brain Diseases - Stock Titan
NKGen Biotech and HekaBio enter strategic partnership to bring novel NK cell therapy to Japan - BioSpectrum Asia
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - The Manila Times
NKGen Biotech Partners with HekaBio for SNK01 in Japan - TipRanks
NKGen and HekaBio partner to advance NK cell therapy in Japan - Investing.com India
NKGen and HekaBio partner to advance NK cell therapy in Japan By Investing.com - Investing.com South Africa
Vivos Therapeutics shares rise 1.81% premarket after NKGen Biotech's new funding announcement. - AInvest
Revolutionary NK Cell Therapy Targets Alzheimer's: NKGen Secures Fast-Track Access to Japanese Market - Stock Titan
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire
NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World
Nkgen Biotech Inc (NKGN) 재무 분석
Nkgen Biotech Inc (NKGN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
5.47%
1.59%
자본화:
|
볼륨(24시간):